ERBB2 and breast cancer: Across solid tumours, PIK3CA mutations (PIK3CAmut) are commonly observed in hormone receptor‐positive, HER2‐negative (HR+, HER2−) breast cancers, with a prevalence of ~ 40% [2, 3].